Table 4.
Hypoglycaemic and hypolipidaemic effect of GLPS
| Models | FBG/(mmol/L) | TC/(mmol/L) | TG/(mmol/L) | References | ||||
|---|---|---|---|---|---|---|---|---|
| Groups | Concentration | P‐value | Concentration | P‐value | Concentration | P‐value | ||
| Wistar rats (8/group) | Normal control | 4.90 ± 0.70 | – | 0.78 ± 0.06 | – | 0.35 ± 0.08 | – | 62 |
| DM | 16.93 ± 2.42 | <.01 | 0.81 ± 0.07 | – | 0.51 ± 0.11 | <.05 | ||
| DM+GLPS | 11.80 ± 1.71 | <.01 | 0.74 ± 0.08 | <.05 | 0.46 ± 0.05 | <.05 | ||
| DS (DM + sporting) | 12.30 ± 2.10 | <.01 | 0.75 ± 0.06 | <.05 | 0.44 ± 0.06 | <.05 | ||
| DS+GLPS | 9.18 ± 1.28 | <.01 | 0.72 ± 0.04 | <.01 | 0.40 ± 0.10 | <.05 | ||
| Wistar rats (8/group) | Normal control | 4.7 ± 0.2 | – | 2.46 ± 0.23 | – | 0.61 ± 0.04 | – | 61 |
| High‐fat/fructose diet | 4.8 ± 0.2 | – | 2.55 ± 0.15 | – | 0.65 ± 0.07 | – | ||
| DM | 16.8 ± 0.7 | – | 3.78 ± 0.91 | – | 1.10 ± 0.05 | – | ||
| PSG‐1 | 12.4 ± 1.0 | <.01 | 2.59 ± 0.12 | <.05 | 0.89 ± 0.08 | <.05 | ||
| Cyclosporin A | 17.1 ± 1.4 | – | 2.80 ± 0.22 | – | 1.14 ± 0.04 | – | ||
| N‐acetyl‐L‐cysteine | 15.6 ± 1.2 | – | 2.78 ± 0.10 | – | 1.09 ± 0.13 | – | ||
| SD rats (10/group) | Normal control | 2.99 ± 0.47 | – | 1.90 ± 0.12 | <.01 | 0.84 ± 0.11 | <.05 | 59 |
| DM | 12.93 ± 1.91 | – | 2.87 ± 0.18 | – | 2.56 ± 0.73 | – | ||
| GLPS‐L (100 mg/mL) | 7.64 ± 0.94 | <.01 | 2.38 ± 0.24 | <.01 | 2.04 ± 0.18 | <.01 | ||
| GLPS‐M (200 mg/mL) | 7.47 ± 0.87 | <.01 | 2.29 ± 0.21 | <.01 | 1.77 ± 0.27 | <.01 | ||
| GLPS‐H (400 mg/mL) | 5.51 ± 0.77 | <.01 | 2.15 ± 0.13 | <.01 | 1.01 ± 0.19 | <.01 | ||
| Metformin | 4.63 ± 0.80 | <.01 | 2.08 ± 0.12 | <.01 | 1.62 ± 0.12 | <.01 | ||
| SD rats (10/group) | Normal control | – | – | 1.35 ± 0.21 | – | 0.42 ± 0.23 | – | 64 |
| Hyperlipidaemia | – | – | 9.13 ± 2.17 | <.01 | 1.19 ± 0.21 | <.01 | ||
| GLPS‐L (200 mg/kg) | – | – | 5.52 ± 1.29 | <.01 | 0.83 ± 0.22 | <.01 | ||
| GLPS‐M (400 mg/kg) | – | – | 6.23 ± 1.75 | <.01 | 0.82 ± 0.22 | <.01 | ||
| GLPS‐H (800 mg/kg) | – | – | 5.85 ± 1.62 | <.01 | 0.80 ± 0.26 | <.01 | ||
| SD rats (10/group) | Normal control | 4.46 ± 0.44 | – | 1.49 ± 0.28 | – | 1.32 ± 0.24 | – | 63 |
| DM | 22.60 ± 2.46 | – | 1.68 ± 0.20 | – | 1.60 ± 0.46 | – | ||
| GLPS‐L (100 mg/kg) | 12.04 ± 1.21 | <.05 | 1.32 ± 0.24 | <.05 | 1.04 ± 0.21 | <.05 | ||
| GLPS‐M (200 mg/kg) | 9.82 ± 1.31 | <.05 | 1.02 ± 0.20 | <.05 | 0.92 ± 0.18 | <.05 | ||
| GLPS‐H (400 mg/kg) | 8.69 ± 1.25 | <.01 | 0.89 ± 0.19 | <.01 | 0.85 ± 0.15 | <.01 | ||
| SD rats (10/group) | Hyperlipidaemia | – | – | 9.13 ± 2.17 | – | 1.19 ± 0.21 | – | 61 |
| GLPS‐L (100 mg/kg) | – | – | 5.52 ± 1.29 | <.01 | 0.83 ± 0.17 | <.01 | ||
| GLPS‐M (200 mg/kg) | – | – | 6.23 ± 1.75 | <.01 | 0.82 ± 0.22 | <.01 | ||
| GLPS‐H (400 mg/kg) | – | – | 5.85 ± 1.62 | <.01 | 0.80 ± 0.26 | <.01 | ||
| SD rats (10/group) | Normal control | 5.00 ± 0.00 | – | 2.01 ± 0.29 | – | 1.13 ± 0.16 | – | 60 |
| DM | 25.00 ± 3.92 | <.05 | 4.38 ± 0.34 | <.05 | 1.74 ± 0.18 | <.05 | ||
| Metformin | 13.53 ± 1.82 | <.05 | 2.68 ± 0.36 | <.05 | 1.38 ± 0.09 | <.05 | ||
| GLPS | 16.61 ± 2.26 | <.05 | 3.57 ± 0.64 | <.05 | 1.54 ± 0.12 | <.05 | ||
| Pregnant rats (8/group) | Normal control | 5.6 ± 1.5 | <.01 | – | – | – | – | 57 |
| DM | 21.3 ± 1.9 | – | – | – | – | – | ||
| GLPS | 8.7 ± 1.6 | <.01 | – | – | – | – | ||
| Kunming species mouse (8/group) | Normal control | 5.98 ± 0.27 | <.05 | – | – | – | – | 89 |
| DM | 32.53 ± 0.37 | – | – | – | – | – | ||
| GLPS‐L (100 mg/kg) | 31.97 ± 0.22 | – | – | – | – | – | ||
| GLPS‐M (200 mg/kg) | 20.01 ± 0.14 | <.05 | – | – | – | – | ||
| GLPS‐H (400 mg/kg) | 17.96 ± 0.49 | <.05 | – | – | – | – | ||
| SD rats (16/group) | Normal control | 4.38 ± 0.40 | – | – | – | – | – | 56 |
| DM | 22.81 ± 1.41 | – | – | – | – | – | ||
| GLPS‐L (0.1 g/kg) | 11.33 ± 0.40 | <.05 | – | – | – | – | ||
| GLPS‐M (0.2 g/kg) | 9.56 ± 0.23 | <.05 | – | – | – | – | ||
| GLPS‐H (0.3 g/kg) | 7.23 ± 0.36 | <.05 | – | – | – | – | ||
| Kunming species mouse (10/group) | DM | 37.01 ± 7.80 | – | – | – | – | – | 54 |
| GLPS‐L (100 mg/kg) | 22.40 ± 6.01 | <.01 | – | – | – | – | ||
| GLPS‐M (200 mg/kg) | 23.87 ± 7.77 | <.01 | – | – | – | – | ||
| GLPS‐H (400 mg/kg) | 23.82 ± 6.43 | <.01 | – | – | – | – | ||
| Wistar rats (6/group) | Normal control | 5.71 ± 0.7 | – | – | – | – | – | 43 |
| DM | 22.14 ± 1.91 | <.01 | – | – | – | – | ||
| GLPS‐L (60 mg/kg) | 17.32 ± 0.98 | <.01 | – | – | – | – | ||
| GLPS‐M (120 mg/kg) | 14.38 ± 1.23 | <.01 | – | – | – | – | ||
| GLPS‐H (180 mg/kg) | 8.43 ± 0.72 | <.01 | – | – | – | – | ||
GLPS, Ganoderma lucidum polysaccharides; TC, triglycerides; TG, total cholesterol; FBG, fasting blood glucose.